Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04112667 · ClinicalTrials.gov registry record

Functionally Validated Structural Endpoints for Early AMD

A clinical trial of Aging and Age-related Macular Degeneration, sponsored by Cynthia Owsley.

Completed
Registry status
556
Enrollment target
1
Study location

NCT04112667: Completed study of Aging and Age-related Macular Degeneration, sponsored by Cynthia Owsley.

NCT04112667 is a study of Aging and Age-related Macular Degeneration that has completed, run by Cynthia Owsley. The registered enrollment target is 556 participants, below the 2,193-participant average among 262 other Aging trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04112667, a study of Aging and Age-related Macular Degeneration, has completed, sponsored by Cynthia Owsley.

COMPLETED
Registry status
556 participants
Enrollment target
1
Study location

Study Summary

Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using cellular- and subcellular level imaging of the retina and its supporting tissues in living people. An accurate map and timeline of structure-function relationships in persons tested for night vision will result in functionally validated structural endpoints for early AMD trials, as well as define major biologic effects for development into future treatments.

Primary Outcome

Time required to recover light sensitivity after exposure to bright light

Interventions

  • OTHER Normal Macular Health
  • OTHER Early Macular Degeneration
  • OTHER Young Normals

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 556 participants
Start Date 2019-10-07
Est. Completion 2024-10-31
Cynthia Owsley

1 total trials

What the finished NCT04112667 record still lists

NCT04112667 is an observational study that tracks outcomes without assigning an intervention. The registered 556 participants enrollment target is mid-sized for trials with a published cap, below the 2,193-participant average among 262 other Aging trials with a reported enrollment target (75% lower).

The record links to 2 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Normal Macular Health is the first listed.

NCT04112667 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT04112667 about?

NCT04112667 is a clinical study titled "Functionally Validated Structural Endpoints for Early AMD". Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using...

What is the current status of trial NCT04112667?

This trial is currently completed. The enrollment target is 556 participants. The study started on 2019-10-07. Estimated completion is 2024-10-31.

What conditions does trial NCT04112667 study?

This clinical trial studies the following conditions: Aging, Age-related Macular Degeneration.

What interventions are being tested in trial NCT04112667?

The interventions under investigation include: Normal Macular Health (OTHER), Early Macular Degeneration (OTHER), Young Normals (OTHER).

Who is sponsoring clinical trial NCT04112667?

This trial is sponsored by Cynthia Owsley, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04112667 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04112667's enrollment target sits among peer trials

556 22nd of 262 higher than 241 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06074588 · 556 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  • NCT06693622 · 556 participants

    Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

  • NCT05708885 · 557 participants · NA

    Striated Esophageal Motor Function Modulation in Health and Disease

  • NCT06799000 · 555 participants · Phase 3

    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04112667, the US trial registry maintained by the National Library of Medicine. NCT04112667 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.